In this episode of "The Top Line," we talk with Fierce’s Eric Sagonowsky and Kevin Dunleavy about the most expensive drugs in the U.S. We also cover Eli Lilly's recent acquisition, the latest company to challenge the Inflation Reduction Act, and the rest of the week's headlines.
To learn more about the topics in this episode:
- 'Misinformation': AstraZeneca's China head refutes news report about potential spinoff
- Deadline extended: Biopharma's collective memory of COVID—in photographs
- Lilly makes fresh bet on IL-17 with $2.4B acquisition of Dice Therapeutics
- Bristol Myers follows Merck's lead with its own lawsuit blasting IRA's Medicare negotiations
- Most expensive drugs in the US in 2023
"The Top Line" is produced by senior podcast producer Teresa Carey. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.
We’d love to hear from you! If you have a comment about this podcast or if you have a tip for a future episode of The Top Line, you can reach us at this link.